Immortals Review: What Its GLP-1 Documentation Establishes—and What It Does Not

A medication menu can tell you what a telehealth company markets without showing how well its particular program works. That distinction matters at Immortals, where GLP-1 treatments sit inside a broader longevity business. The company advertises compounded semaglutide and tirzepatide with glycine and B12, alongside Wegovy, Zepbound KwikPen and Foundayo. Those listings establish advertised offerings—not clinical equivalence among formulations, verified availability for every patient or measured results from Immortals care.

This review examines public documentation consulted October 19, 2026, separating the company’s descriptions from independent clinical and regulatory context. The practical picture is specific: physician review precedes prescribing and payment, discounted medication prices carry quarterly upfront commitments, and a separate biomarker subscription has its own geography and benefits. Important gaps remain around dispensing pharmacies, membership costs, exact product quantities and follow-up responsibilities. Understanding what provider documents can prove is the starting point, rather than treating a polished product page as a clinical study.

At a glance

Clinical access: Immortals describes a telehealth platform connecting adults with licensed physicians; prescriptions require assessment and are not guaranteed.
Sources: [8]
Compounded offerings: The company advertises weekly injectable compounded tirzepatide and semaglutide with glycine and B12, and acknowledges that compounded formulations are not FDA approved.
Sources: [9] [12] [8]
Discount conditions: Displayed member prices include $217/month for compounded tirzepatide and $167/month for compounded semaglutide, each billed quarterly with a three-month commitment paid upfront. Membership cost is not established.
Sources: [9] [12]
Refund boundary: The medicine-specific policy states that all sales are final, with no returns or refunds, and directs customers to contact the company about suspected prescription-filling errors.
Sources: [10]
Separate laboratory subscription: Biomarker Tests is advertised at $365/year for two rounds of blood and urine testing plus platform access, with exclusions in five states.
Sources: [13]

A longevity platform is not itself clinical evidence

Immortals’ terms identify Continuance LLC and its subsidiaries as the operator behind services using the Immortals, Blueprint, Don’t Die and Bryan Johnson brands. The website credits Bryan Johnson and Kate Tolo as founders of both Immortals and Blueprint. Its medicine business describes itself as a telehealth platform designed by longevity experts that connects users with licensed physicians. These details establish the company’s stated identity and positioning, not independent validation of its medical protocols.

The website presents Carl Seger, M.D., as a board-certified physician specializing in preventive and longevity medicine. That is a provider-reported credential, not a licensing verification performed for this review. Similarly, language about supporting longevity describes the purpose the company assigns to treatment. The consulted documentation does not establish that enrolling in Immortals extends life, nor does it provide provider-specific outcome data demonstrating the performance of its GLP-1 program.

The broader digital offering also needs to be separated from medical care. Immortals says its app and uploads of outside biomarker results are free, with testing, prescriptions and supplements optional. However, the homepage also includes an app “COMING SOON” statement, leaving availability inconsistently described. Its terms say AI tools do not provide medical advice and may be inaccurate. An app-generated longevity protocol therefore should not be confused with a physician’s prescription or a validated treatment outcome.

Sources: [11] [14] [8]

The medication menu contains distinct evidence questions

Immortals lists compounded tirzepatide with glycine and B12 in a weekly injectable form, with “Personalized Dose” and “Microdose” options. It also lists compounded semaglutide with glycine and B12 as a weekly injection. The tirzepatide page suggests that added ingredients may support muscle maintenance and nutrient deficiencies during a caloric deficit. That remains a commercial claim in this documentation; the clinical context reviewed here does not establish those benefits for the company’s blend.

The other listings should not be collapsed into the compounded offerings. The Wegovy page identifies semaglutide and displays tablet and injection choices, but the available text does not unambiguously connect the displayed price to either presentation. The Zepbound KwikPen page identifies tirzepatide as a weekly GIP/GLP-1 receptor agonist injection. Foundayo is described by Immortals as orforglipron in a daily oral tablet. These are descriptions of the advertised products, not independent regulatory verification of every listing.

Ingredient names alone do not answer whether evidence transfers to a different preparation, route or schedule. In particular, a branded-drug study cannot automatically substantiate an Immortals compounded blend or its microdose option. Our guide to formulation and route explains why those distinctions matter. Before comparing prices or expected benefits, readers need the exact product, presentation, concentration and supplied quantity—not simply a familiar molecule’s name.

Sources: [9] [12] [7] [6] [5] [3] [4]

What research and FDA guidance add

Independent trials provide context, not a performance report for Immortals. STEP 1 studied subcutaneous semaglutide in adults with obesity or overweight plus a weight-related condition, without diabetes; SURMOUNT-1 studied subcutaneous tirzepatide in a comparable broad population excluding diabetes. Neither was a trial of this provider, its glycine-and-B12 preparations or microdose offerings. Their findings cannot establish individual results, and comparing separate trials does not create a randomized head-to-head comparison.

Immortals explicitly acknowledges that its compounded formulations are not FDA approved and have not been evaluated by FDA for safety, quality or efficacy. FDA likewise explains that compounded drugs do not undergo its premarket review. Nonapproval alone does not demonstrate clinical inequivalence, but it also cannot establish equivalence. FDA recommends compounded drugs when an individual’s medical needs cannot be met by an FDA-approved drug, with a prescription and a state-licensed pharmacy.

The useful distinction is between evidence for a studied product and evidence for a particular service or formulation. FDA approval attaches to a specific product, not to the telehealth platform arranging care. Readers can explore approved medicines and compounded preparations without assuming that either a longevity narrative or an ingredient match resolves the question. The consulted Immortals pages do not identify the dispensing pharmacies by name, limiting documentary assessment of that part of the service.

Sources: [8] [9] [1] [3] [4]

What the displayed prices actually commit you to

The medication pages show a subtotal alongside a lower member amount. Their footnote is material: the starred member price is billed quarterly with a three-month commitment paid upfront. These are not documented as commitment-free monthly payments. The cost and full conditions of Immortals Membership are not established in the consulted material, so the discounted figures cannot be treated as the complete cost of joining and receiving medication.

The table preserves the displayed figures rather than calculating annual costs or projected savings. The company says pricing varies by medication and dose, while exact quantities and price-to-variant assignments remain unclear. This is especially important for Wegovy’s tablet and injection choices and for personalized or microdose selections. Several pages repeat a potential annual savings figure despite different monthly discounts; the documentation does not explain that calculation well enough to use it as a reliable comparison.

Immortals also says membership fees are not required to access treatment and that payment occurs only after physician approval. That can coexist with optional membership discounts, but it leaves a practical question: what is the complete nonmember checkout price versus the complete member checkout price? The statement that insurance is not required does not establish insurance acceptance, coverage or prior-authorization assistance. Inclusion of shipping, injection supplies, video consultations and necessary laboratory work is also not clear.

Advertised medication prices; every member figure below carries quarterly billing and a three-month commitment paid upfront. Membership cost is not established.
Advertised medication	Displayed subtotal	Displayed member price and limitation
Compounded tirzepatide with glycine and B12; weekly injection	$255/month	$217/month; supplied quantity and selected dose option not confirmed
Compounded semaglutide with glycine and B12; weekly injection	$196/month	$167/month; supplied quantity and selected dose option not confirmed
Wegovy, identified as semaglutide	$1,550/month	$1,317/month; price cannot be assigned confidently to tablets or injections
Zepbound KwikPen, identified as tirzepatide injection	$600/month	$510/month; exact supplied quantity not confirmed
Foundayo, described as orforglipron oral tablets	$750/month	$637/month; exact supplied quantity not confirmed

Sources: [8] [9] [12] [7] [6] [5]

From intake to prescription: a documented outline, not a guarantee

Immortals advertises medicine access for adults 18 and older in eligible U.S. states, with additional restrictions by medication. Its general terms list all 50 states, but that does not mean every medication is available everywhere. The tirzepatide page says the product is not recommended for people with a personal or family history of medullary thyroid cancer or MEN2, and states that the physician will assess whether treatment is appropriate. The initial form is described as taking five to ten minutes and asks about medical history, current medicines, goals and treatment preferences. A physician reviews each case before a prescription is issued; enrollment does not guarantee approval.

Some states may require a synchronous audio or video consultation before prescribing. The timing claims are less uniform: the collection page says review is typically completed within 24 hours, while product pages describe physician review within 72 hours. Neither should be read as an unconditional promise. The documentation also does not provide a medication-by-state availability map or establish the BMI thresholds used by the service, so broad geographic access cannot settle individual eligibility.

For practical preparation, the missing item is not a generic screening checklist but a clear assignment of responsibility. The consulted pages do not name the clinical entity responsible for consultations and prescriptions. Readers should establish who will conduct the assessment, whether a live appointment is required in their state, what additional information may be requested and what happens if treatment is declined. The company’s approval-before-charge statement is useful, but does not resolve every possible checkout or service-fee question.

Sources: [8] [9] [11]

Delivery and follow-up need separate verification

The collection page says most medications ship in two to five business days after review and prescribing. The tirzepatide page advertises discreet packaging, a two-to-five-business-day shipping interval and an overall intake-to-door window of three to seven days. These statements describe different stages and are not interchangeable. Dispatch is not arrival, and the overall advertised window does not remove the need to clarify review time, pharmacy processing and transit for the actual prescription.

The consulted documentation does not establish the carrier, package tracking, refrigeration requirements or procedures for delayed, damaged or missing shipments. FDA’s advice supplies an important boundary: do not use an injectable GLP-1 drug that arrives warm or with insufficient refrigeration; contact the provider or dispensing pharmacy. FDA also reports measurement and administration errors involving compounded medication, some associated with hospitalization. Instructions should be clarified with the prescriber or pharmacist, not reconstructed from a review.

Immortals advertises unlimited doctor messaging, chat access for additional support and available video consultations, with an “up to 12 months” label. It does not state a response-time standard or clearly establish whether video visits carry separate charges. That support window is not proof of a year-long medication supply or a price lock. As our guide to clinical follow-up explains, ongoing care should address response and tolerability, not merely access to renewals.

Sources: [8] [9] [1] [2]

Biomarker testing is a separate purchase, not proof of treatment benefit

Immortals advertises a Biomarker Tests membership at $365 per year. The stated package includes two comprehensive blood panels and urine tests annually, access to the Biomarkers platform, more than 100 unique biomarkers and at least 160 measurements. Other page language uses different test and measurement totals, which should not be treated as interchangeable counts of unique biomarkers. The subscription is a documented testing offering, not evidence that its GLP-1 formulations improve longevity.

Initial and follow-up appointments are scheduled through the platform at a local Quest Diagnostics laboratory. Customers must be at least 18 and based in the United States; Arizona, Hawaii, New Jersey, New York and Rhode Island are excluded. These exclusions belong to the biomarker program and should not be transferred automatically to medicine access. Likewise, the laboratory page’s claim that 95% receive complete results within two weeks is a testing turnaround claim, not a medication-delivery estimate.

The testing page also advertises an HSA/FSA eligibility review. If approved, a customer receives a letter of medical necessity in one to two days to submit with a receipt for reimbursement. That process is not a guarantee of reimbursement and does not establish equivalent terms for prescriptions. Before buying testing alongside medication, readers should ask whether their treating clinician requires it, will interpret it and considers it separate from any additional treatment-specific laboratory requirements.

Sources: [13]

Renewal and refund terms matter when evidence leaves questions open

The medicine-specific policy states that all sales are final and that returns and refunds are unavailable. It invites contact if the customer believes a prescription-filling error occurred, but does not promise a particular remedy. The general terms also contain legal exceptions and discretionary refund language. Those broader provisions should not be presented as a routine money-back option for medication, especially when the advertised discounted purchase involves a three-month upfront commitment.

General subscription terms provide for automatic renewal and require cancellation at least 24 hours before the current period ends to avoid the next subscription charge. Cancellation is available through account settings, stops future charges and becomes effective at the end of the current period. Applicable taxes and transaction fees may also be billed. The documentation does not clearly map those general rules onto every medication plan, membership or prescription-renewal process.

A useful final check is a written explanation of the selected plan: the full initial charge, membership charge if any, renewal date, cancellation route and handling of a clinical decision not to continue. Cancellation does not imply a refund of an already purchased period. For filling concerns, the policy directs customers to contact the company; for subscription cancellation, it identifies account settings. Clear answers before payment would resolve more uncertainty than another broad claim about personalization.

Sources: [10] [11] [9] [12]

Questions & answers

Does Immortals require a paid membership for medication?

Its product page says membership fees are not required to access treatment. However, the lower displayed prices are member prices, and the cost of that membership is not established. Ask for both complete checkout totals before comparing options. The advertised starred member amounts require quarterly billing and a three-month commitment paid upfront; they are not simply monthly cancel-anytime offers.

Sources: [9] [12]

Are Immortals’ compounded injections FDA approved?

No. Immortals acknowledges that its compounded formulations are not FDA approved. That does not by itself establish clinical inequivalence, but studies of other products do not verify these blends. FDA recommends compounded drugs when a patient’s medical needs cannot be met by an approved drug, with a prescription and a state-licensed pharmacy. The consulted pages do not name Immortals’ dispensing pharmacies.

Sources: [8] [9] [1]

Can adults in every state obtain every advertised medicine?

The general terms list services in all 50 states, but Immortals Medicine specifies adults 18 and older in eligible states and says some medicines are unavailable in some states. The documentation does not provide a complete medication-specific map. The separate biomarker program excludes Arizona, Hawaii, New Jersey, New York and Rhode Island; those exclusions should not be assumed to describe medication access.

Sources: [11] [8] [13]

How quickly does Immortals review an intake and send medication?

The collection page says review is typically completed within 24 hours; product pages say within 72 hours. Most medications are described as shipping two to five business days after review and prescribing, while a separate headline advertises three to seven days from intake to door. These are different claims, not one guaranteed delivery deadline. State-required live consultation could also be part of the process.

Sources: [8] [9]

What follow-up access does Immortals advertise?

The product page advertises unlimited messaging with the doctor, chat support and available video consultations, alongside an “up to 12 months” statement. It does not specify a response deadline, appointment frequency or whether video consultations are included in each medication price. Confirm who handles side effects, prescription questions and urgent concerns, rather than interpreting anytime messaging as an immediate-response or emergency-care service.

Sources: [9]

Will canceling return money already paid for medicine?

Cancellation is not a documented refund entitlement. The medicine policy says sales are final, with no returns or refunds, while directing suspected filling errors to the company. General terms say account-settings cancellation stops future charges and takes effect at the period’s end, with at least 24 hours’ notice required before renewal. Ask how those rules apply to the exact medication plan before paying upfront.

Sources: [10] [11]

Our assessment

Immortals documents a recognizable telehealth pathway: adult intake, physician assessment, conditional prescribing, direct shipment and advertised messaging support. It also discloses compounded-drug nonapproval and publishes medication prices with consequential quarterly upfront conditions. Those are useful disclosures. They do not establish outcomes for its blends, microdose options or longevity positioning. The largest decision gaps are the unnamed dispensing pharmacies and clinical entity, unknown membership cost, uncertain presentation-to-price assignments and incomplete explanation of included services and renewal rules. The separate biomarker subscription adds a concrete testing option, not proof of treatment effectiveness. A reasonable documentary conclusion is that Immortals offers a substantive advertised GLP-1 service, but readers still need a product-specific, all-in written plan before judging its cost, responsibilities and relevance to their clinician-assessed needs.

Visit Immortals’s official site ↗

This opens the reviewed business’s website. The link is not a prescription or endorsement. Commercial relationships.

Sources & documentation

Public materials consulted October 19, 2026. Provider statements are attributed claims, not independently verified clinical outcomes. Terms can change; obtain a current written quote.

Immortals Review: What Its GLP-1 Documentation Establishes—and What It Does Not

At a glance

01A longevity platform is not itself clinical evidence

02The medication menu contains distinct evidence questions

03What research and FDA guidance add

04What the displayed prices actually commit you to

05From intake to prescription: a documented outline, not a guarantee

06Delivery and follow-up need separate verification

07Biomarker testing is a separate purchase, not proof of treatment benefit

08Renewal and refund terms matter when evidence leaves questions open